Pictet Asset Management (Switzerland)’s Nurix Therapeutics NRIX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$9.3M	Sell	930,914 -133,924	-13%	-$1.37M	0.01%	637
2023 Q1	$9.46M	Buy	1,064,838 +102,481	+11%	+$1.07M	0.01%	627
2022 Q4	$10.6M	Sell	962,357 -113,992	-11%	-$1.37M	0.02%	582
2022 Q3	$14M	Sell	1,076,349 -354,016	-25%	-$5.6M	0.02%	502
2022 Q2	$18.1M	Sell	1,430,365 -8,917	-0.6%	-$101K	0.03%	481
2022 Q1	$20.2M	Buy	1,439,282 +317,347	+28%	+$5.63M	0.02%	495
2021 Q4	$32.5M	Buy	1,121,935 +194,385	+21%	+$5.89M	0.03%	424
2021 Q3	$27.8M	Buy	+927,550	New	+$28.6M	0.03%	442

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s NRIX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Nurix Therapeutics (NRIX) stake by 13% in Q2 2023, selling an estimated $1.37M and leaving 930,914 shares worth $9.3M. The position accounts for 0.01% of the portfolio, ranked #637.

Pictet Asset Management (Switzerland) first reported a position in NRIX in Q3 2021 and has held it in 8 quarters since. The position peaked at $32.5M in Q4 2021. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

Pictet Asset Management (Switzerland) held 930,914 shares of Nurix Therapeutics worth $9.3M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 133,924 Nurix Therapeutics shares in Q2 2023, an estimated $1.37M.
Nurix Therapeutics made up 0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #637 holding.
Pictet Asset Management (Switzerland) first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Nurix Therapeutics position peaked at $32.5M in Q4 2021.
126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.